Parnassia Addiction Research Centre

What Parnassia Addiction Research Centre does

Parnassia Addiction Research Centre (PARC) is the dedicated scientific research institute of Parnassia Groep, a major Dutch mental health and addiction care provider. Founded approximately in 1998 and headquartered in The Hague, Netherlands, PARC has conducted research into addiction and related individual, social, and societal problems for over 25 years. The organization operates as a non-profit research entity and does not sell commercial products or services. Its research program covers pharmacological and psychosocial treatments, early detection and interventions, youth and addiction, recovery-oriented care, psychiatric comorbidity, and personalized interventions.

PARC's core activities are organized around clinical trials and longitudinal cohort studies. The flagship adult study, REDUCE, is a multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of sustained-release dexamphetamine for cocaine use disorder, enrolling 204 patients across Antes, Brijder, and GGD Amsterdam. On the youth side, the Youth in Transition (YIT) study is a longitudinal cohort following over 420 adolescents who entered addiction treatment, with a 90% two-year follow-up rate. Other active programs include RECAB, the first Dutch clinical trial of abstinence-focused contingency management for cannabis use disorder in youth, and PACT, which examines therapeutic alliance and outcomes. Findings are disseminated through peer-reviewed journals including The Lancet, BMC Psychiatry, and European Addiction Research, with publications catalogued annually since 2020.

PARC's business model is grant-funded rather than revenue-generating. Primary funding flows from ZonMw, the Netherlands Organisation for Health Research and Development, across programs including Goed Gebruik Geneesmiddelen (Rediscovery) and Research Program GGz. The institute is operationally embedded within Parnassia Groep, with affiliated access to clinical sites such as Brijder addiction treatment centers and Parnassia Groep Academie for training. Customer segments are effectively the addiction treatment centers and healthcare providers that participate in trials, the youth and adult populations enrolled as study subjects, and the broader Dutch public health system that benefits from evidence-based treatment guidance.

Name

Parnassia Addiction Research Centre

Legal name

Parnassia Addiction Research Centre

Website

https://parc-addictionresearch.nl

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

11–50 employees

Short description

Parnassia Addiction Research Centre (PARC) is the non-profit research institute of Parnassia Groep, conducting clinical trials and longitudinal studies on addiction treatment for over 25 years. It serves Dutch addiction care providers and patients through ZonMw-funded scientific research.

Ownership category

akta.pro rank

Product category

Addiction Research Services

NAICS

Research and Development in the Social Sciences and Humanities (541720), Outpatient Mental Health and Substance Abuse Centers (62142)

SIC

Services-Social Services (8300)

akta.pro primary industry

Outpatient Substance Use Disorder (SUD) Treatment Programs (HLAFABAD)

akta.pro secondary industry

Substance Use Disorder Prevention & Recovery Services (BPAGACAE)

Keywords

• Addiction research
• Clinical trials
• Substance use disorder
• Addiction medicine
• Longitudinal cohort studies

Headquarters

HQ city

Den Haag

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D

Revenue model

1. Research Grants and Funding: PARC is funded primarily through research grants from ZonMw (Netherlands Organisation for Health Research and Development), including funding for the REDUCE study (Goed Gebruik Geneesmiddelen - Rediscovery program) and YIT study (Research Program GGz).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Parnassia Addiction Research Centre (PARC) is the research institute of Parnassia Groep conducting scientific research into addiction and related individual, social, and societal problems. The organization runs clinical trials, longitudinal cohort studies, and care evaluation projects focused on pharmacological and psychosocial treatments for substance use disorders in youth and adults.

Product overview

Parnassia Addiction Research Centre (PARC) is the research institute of Parnassia Groep, conducting scientific research into addiction and related individual, social, and societal problems for over 25 years. The organization operates as a research center focused on clinical trials and longitudinal studies rather than commercial products. Its main offerings include research studies for youth (YIT, RECAB, PACT) investigating factors affecting addiction trajectories and treatment outcomes, and studies for adults (REDUCE) examining pharmacological treatments for cocaine use disorder. Additionally, PARC provides care registration and evaluation services. The research focuses on themes including addiction, pharmacological and psychosocial treatments, early detection, youth and addiction, recovery-oriented care, psychiatric comorbidity, and development of personalized interventions.

Differentiator

Problem solved

Functional benefit

Products and services

• Youth in Transition (YIT) A longitudinal cohort study following over 420 adolescents who started addiction treatment, investigating factors affecting treatment and addiction trajectories over a 4-year period.
• RECAB The first clinical trial in the Netherlands investigating the effectiveness and cost-effectiveness of abstinence-focused contingency management (CM) for young people with cannabis use disorder.
• PACT Study examining therapeutic alliance, client feedback, and outcomes in the treatment of adolescents in youth psychiatry and addiction treatment.
• REDUCE A multicenter, randomized, double-blind, placebo-controlled clinical trial investigating the efficacy and safety of sustained-release dexamphetamine in individuals with cocaine use disorder.
• Zorgregistratie/Evaluatie Care registration and evaluation services for both youth and adult addiction treatment programs.

Quantifiable outcome

• REDUCE study published results in The Lancet (2016 CATCH study) described as 'a milestone' for proving efficacy of sustained-release dexamphetamine
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• AntescoreStrategic or Co-development PartnerAntes is one of three major addiction treatment centers participating in the REDUCE study, a multicenter clinical trial investigating the efficacy of sustained-release dexamphetamine for cocaine use disorder.
• BrijdercoreStrategic or Co-development PartnerBrijder is part of Parnassia Groep and serves as a key partner in conducting the REDUCE clinical trial at addiction treatment centers.
• GGD AmsterdamcoreStrategic or Co-development PartnerGGD Amsterdam (Municipal Health Service) collaborates in the REDUCE study as part of the multicenter clinical trial investigating cocaine use disorder treatment.
• Stichting Het Zwarte GatminorStrategic or Co-development PartnerStichting Het Zwarte Gat collaborates in the REDUCE study, contributing to the research on cocaine use disorder treatment.
• Parnassia GroepcoreStrategic or Co-development PartnerPARC is the research institute of Parnassia Groep, conducting scientific research into addiction and related problems on behalf of the healthcare organization for over 25 years.
• Parnassia Groep AcademiecoreStrategic or Co-development PartnerThe Parnassia Groep Academie is part of the same organization, supporting education and training alongside PARC's research activities.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Jellinek (Arkin): Jellinek is a major Dutch addiction treatment provider (now part of Arkin), historically similar in scope and mission to Parnassia Groep's addiction care arm (Brijder). Comparable as a regional addiction care delivery platform that PARC's research directly informs and could partner with.

Direct peers

• King's College London — Addictions, IoPPN: The Addictions Department within King's College London's Institute of Psychiatry, Psychology & Neuroscience is one of Europe's leading academic addiction research groups, conducting clinical trials and longitudinal studies on substance use disorders — directly comparable to PARC's research portfolio.
• Trimbos Institute: The Trimbos Institute is the Dutch national knowledge center for mental health and addiction, conducting applied research, monitoring, and prevention programs. It is the closest Dutch peer to PARC, sharing the national policy-research orientation and focus on substance use disorders.
• National Drug and Alcohol Research Centre (NDARC): NDARC at UNSW Sydney is a dedicated national addiction research center conducting clinical trials and cohort studies on alcohol and drug use disorders. Like PARC, it operates as a specialized research institute embedded in a larger university/health system, with a similar mix of pharmacological and longitudinal research.

Broad incumbents

• Centre for Addiction and Mental Health (CAMH): CAMH is Canada's largest mental health and addiction teaching hospital and research center. It is comparable to PARC in combining clinical care, research, and policy influence, though at significantly greater scale and with a broader mandate spanning all behavioral health conditions.

Emerging players

• Nijmegen Institute for Scientist-Practitioners in Addiction (NISPA): NISPA is a Dutch academic research network at Radboud University focused on addiction science and the Master in Addiction Medicine (MiAM) program — which PARC's PhD candidates have completed. Comparable as an emerging Dutch addiction research hub with academic-clinical integration.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/brijder-onderzoek-parc

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Parnassia Addiction Research Centre